ORIC reports Q3 2023 net loss; cash $256.2M; ORIC-114 CNS responses

Oric Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.46

Cash, cash equivalents and investments $256.2M as of Sept 30, 2023; expected to fund operations into late 2025.
R&D expenses $22.4M in Q3 2023, up from $14.7M in Q3 2022 due to pipeline advancement.
ORIC-114 Phase 1b data at ESMO showed CNS complete response in EGFR exon 20 NSCLC patient; favorable safety.
Initial ORIC-533 data in multiple myeloma to be presented at ASH December 2023.
ORIC-944 initial Phase 1b data in prostate cancer expected Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.